Genetic Abnormalities in Extramedullary Multiple Myeloma

Extramedullary multiple myeloma (or extramedullary disease, EMD) is an aggressive form of multiple myeloma (MM) that occurs when malignant plasma cells become independent of the bone marrow microenvironment. This may occur alongside MM diagnosis or in later stages of relapse and confers an extremely poor prognosis. In the era of novel agents and anti-myeloma therapies, the incidence of EMD is increasing, making this a more prevalent and challenging cohort of patients. Therefore, understanding the underlying mechanisms of bone marrow escape and EMD driver events is increasingly urgent. The role of genomics in MM has been studied extensively; however, much less is known about the genetic background of EMD. Recently there has been an increased focus on driver events for the establishment of distant EMD sites. Generally, high-risk cytogenetic abnormalities and gene signatures are associated with EMD, alongside mutations in RAS signalling pathways. More recently, changes in epigenetic regulation have also been documented, specifically the hypermethylation of DNA promoter regions. Therefore, the focus of this review is to summarize and discuss what is currently known about the genetic background of EMD in MM.

Automated summary

Extramedullary multiple myeloma (EMD) is an aggressive form of multiple myeloma that occurs when malignant plasma cells become independent of the bone marrow microenvironment. The underlying mechanisms of bone marrow escape and EMD driver events are not well understood, but there is increasing focus on high-risk cytogenetic abnormalities, gene signatures, mutations in RAS signalling pathways, and changes in epigenetic regulation. This review aims to summarize and discuss the current knowledge about the genetic background of EMD in MM.